DeepMed Research

BioNTech

🇩🇪Germany

Country: 🇩🇪Germany

Ownership: Public

Employees: 6.1K

Market Cap: $20.7B

Website: http://www.biontech.de

Introduction: BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Oezlem Tuereci, and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.

Clinical Trials

Dose Escalation Trial of BNT152+153 in Patients With Cancer

Phase 1

Active, not recruiting

Conditions: Solid Tumor

Interventions: Drug: BNT152
Drug: BNT153

First Posted Date: 2021-01-14

Last Posted Date: 2025-03-21

Lead Sponsor: BioNTech SE

Target Recruit Count: 86

Registration Number: NCT04710043

Locations: 🇺🇸
Yale Cancer Center, New Haven, Connecticut, United States
🇺🇸
Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois, United States
🇺🇸
Duke Cancer Center, Durham, North Carolina, United States

and more 4 locations

Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy Trial of BNT141 in Patients With Unresectable or Metastatic CLDN18.2-positive Gastric, Pancreatic, Ovarian and Biliary Tract Tumors

Phase 1

Terminated

Conditions: Gastroesophageal Junction Adenocarcinoma
Metastatic Cancer
Cholangiocarcinoma
Pancreatic Cancer
Solid Tumor
Gastric Cancer
Esophageal Adenocarcinoma
Biliary Tract Cancer

Interventions: Drug: BNT141
Drug: Nab-paclitaxel
Drug: Gemcitabine

First Posted Date: 2020-12-24

Last Posted Date: 2024-10-02

Lead Sponsor: BioNTech SE

Target Recruit Count: 13

Registration Number: NCT04683939

Locations: 🇺🇸
City of Hope, Duarte, California, United States
🇺🇸
START, San Antonio, Texas, United States
🇨🇦
University of Montreal - Centre Hospitalier de l´Université de Montréal, Montréal, Canada

and more 4 locations

Safety and Immunogenicity of SARS-CoV-2 mRNA Vaccine (BNT162b2) in Chinese Healthy Population

Phase 2

Completed

Conditions: SARS-CoV-2

Interventions: Biological: BNT162b2
Other: Placebo

First Posted Date: 2020-12-02

Last Posted Date: 2022-05-10

Lead Sponsor: BioNTech SE

Target Recruit Count: 950

Registration Number: NCT04649021

Locations: 🇨🇳
Jiangsu Provincial Center for Disease Control and Prevention, Jiangsu, China

Study to Evaluate the Safety, Tolerability, and Immunogenicity of an RNA Vaccine Candidate Against COVID-19 in Healthy Japanese Adults

Phase 4

Completed

Conditions: SARS-CoV-2 Infection
COVID-19

Interventions: Other: Placebo
Biological: BNT162b2

First Posted Date: 2020-10-19

Last Posted Date: 2023-02-01

Lead Sponsor: BioNTech SE

Target Recruit Count: 160

Registration Number: NCT04588480

Locations: 🇯🇵
SOUSEIKAI Sumida Hospital, Sumida-ku, Tokyo, Japan
🇯🇵
SOUSEIKAI PS Clinic, Fukuoka, Japan

A Trial Investigating the Safety and Effects of One BNT162 Vaccine Against COVID-19 in Healthy Adults

Phase 1

Completed

Conditions: Covid-19
Protection Against COVID-19

Interventions: Biological: BNT162b3

First Posted Date: 2020-09-03

Last Posted Date: 2024-01-05

Lead Sponsor: BioNTech SE

Target Recruit Count: 96

Registration Number: NCT04537949

Locations: 🇩🇪
Contract Research Organization, Mannheim, Germany

A Clinical Trial Investigating the Safety, Tolerability, and Therapeutic Effects of BNT113 in Combination With Pembrolizumab Versus Pembrolizumab Alone for Patients With a Form of Head and Neck Cancer Positive for Human Papilloma Virus 16 and Expressing the Protein PD-L1

Phase 2

Recruiting

Conditions: Unresectable Head and Neck Squamous Cell Carcinoma
Metastatic Head and Neck Cancer
Recurrent Head and Neck Cancer

Interventions: Biological: BNT113
Biological: Pembrolizumab

First Posted Date: 2020-09-01

Last Posted Date: 2025-05-16

Lead Sponsor: BioNTech SE

Target Recruit Count: 350

Registration Number: NCT04534205

Locations: 🇺🇸
California Research Institute, Los Angeles, California, United States
🇺🇸
UCLA Cancer Care, Los Angeles, California, United States
🇺🇸
Stanford Cancer Institute, Palo Alto, California, United States

and more 181 locations

Trial With BNT111 and Cemiplimab in Combination or as Single Agents in Patients With Anti-PD-1-refractory/Relapsed, Unresectable Stage III or IV Melanoma

Phase 2

Active, not recruiting

Conditions: Unresectable Melanoma
Melanoma Stage III
Melanoma Stage IV

Interventions: Biological: BNT111
Biological: Cemiplimab

First Posted Date: 2020-08-26

Last Posted Date: 2025-02-10

Lead Sponsor: BioNTech SE

Target Recruit Count: 184

Registration Number: NCT04526899

Locations: 🇵🇱
Zachodniopomorskie Centrum Onkologii, Szczecin, Poland
🇪🇸
Hospital Universitario Virgen del Rocio, Sevilla, Spain
🇺🇸
Oncology Hematology West P.C. dba Nebraska Cancer Specialists, Omaha, Nebraska, United States

and more 50 locations

Safety and Immunogenicity of SARS-CoV-2 mRNA Vaccine (BNT162b1) in Chinese Healthy Subjects

Phase 1

Completed

Conditions: SARS-CoV-2

Interventions: Other: Placebo
Biological: BNT162b1

First Posted Date: 2020-08-21

Last Posted Date: 2023-09-18

Lead Sponsor: BioNTech SE

Target Recruit Count: 144

Registration Number: NCT04523571

Locations: 🇨🇳
Jiangsu Provincial Center for Disease Control and Prevention, Taizhou, Jiangsu, China

A Phase II Clinical Trial Comparing the Efficacy of RO7198457 Versus Watchful Waiting in Patients with CtDNA-positive, Resected Stage II (high Risk) and Stage III Colorectal Cancer

Phase 2

Recruiting

Conditions: Colorectal Cancer Stage III
Colorectal Cancer Stage II

Interventions: Drug: RO7198457 intravenous (IV)
Other: Observational group (no intervention)

First Posted Date: 2020-07-24

Last Posted Date: 2025-02-06

Lead Sponsor: BioNTech SE

Target Recruit Count: 327

Registration Number: NCT04486378

Locations: 🇪🇸
Hospital Universitario Miguel Servet, Zaragoza, Spain
🇸🇪
Lunds Universitet - Medicinska Fakulteten (Lund University Faculty of Medicine), Lund, Sweden
🇸🇪
Sodersjukhuset, Onkologiska Kliniken, Stockholm, Sweden

and more 115 locations

BNT151 as a Monotherapy and in Combination With Other Anti-cancer Agents in Patients With Solid Tumors

Phase 1

Terminated

Conditions: Solid Tumor

Interventions: Biological: BNT151

First Posted Date: 2020-07-02

Last Posted Date: 2024-06-26

Lead Sponsor: BioNTech SE

Target Recruit Count: 62

Registration Number: NCT04455620

Locations: 🇺🇸
Sarah Cannon Research Institute at Tennessee Oncology, Nashville, Tennessee, United States
🇺🇸
NEXT Oncology, San Antonio, Texas, United States
🇺🇸
Yale Cancer Center, New Haven, Connecticut, United States

and more 3 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy